Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.
Identifieur interne : 009485 ( Main/Exploration ); précédent : 009484; suivant : 009486Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.
Auteurs : Lisa J. Hazard [États-Unis] ; William T. Sause ; R Dirk NoyesSource :
- International journal of radiation oncology, biology, physics [ 0360-3016 ] ; 2002.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (effets indésirables), Antinéoplasiques (usage thérapeutique), Humains, Interféron alpha (effets indésirables), Interféron alpha (usage thérapeutique), Lésions radio-induites (étiologie), Mâle, Mélanome (radiothérapie), Mélanome (traitement médicamenteux), Protéines recombinantes, Radiothérapie adjuvante, Tumeurs cutanées (radiothérapie), Tumeurs cutanées (traitement médicamenteux).
- MESH :
- effets indésirables : Antinéoplasiques, Interféron alpha.
- radiothérapie : Mélanome, Tumeurs cutanées.
- traitement médicamenteux : Mélanome, Tumeurs cutanées.
- usage thérapeutique : Antinéoplasiques, Interféron alpha.
- étiologie : Lésions radio-induites.
- Adulte, Adulte d'âge moyen, Humains, Mâle, Protéines recombinantes, Radiothérapie adjuvante.
English descriptors
- KwdEn :
- Adult, Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Humans, Interferon-alpha (adverse effects), Interferon-alpha (therapeutic use), Male, Melanoma (drug therapy), Melanoma (radiotherapy), Middle Aged, Radiation Injuries (etiology), Radiotherapy, Adjuvant, Recombinant Proteins, Skin Neoplasms (drug therapy), Skin Neoplasms (radiotherapy).
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Interferon-alpha.
- chemical , therapeutic use : Antineoplastic Agents, Interferon-alpha.
- drug therapy : Melanoma, Skin Neoplasms.
- etiology : Radiation Injuries.
- radiotherapy : Melanoma, Skin Neoplasms.
- Adult, Humans, Male, Middle Aged, Radiotherapy, Adjuvant, Recombinant Proteins.
Abstract
Surgically resected melanoma patients with high-risk features commonly receive adjuvant therapy with interferon-alpha 2b combined with radiation therapy; the purpose of our study was to evaluate the potential enhancement of radiation toxicity by interferon.
PubMed: 11849803
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004655
- to stream PubMed, to step Curation: 004655
- to stream PubMed, to step Checkpoint: 004655
- to stream Ncbi, to step Merge: 000874
- to stream Ncbi, to step Curation: 000874
- to stream Ncbi, to step Checkpoint: 000874
- to stream Main, to step Merge: 009858
- to stream Main, to step Curation: 009485
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.</title><author><name sortKey="Hazard, Lisa J" sort="Hazard, Lisa J" uniqKey="Hazard L" first="Lisa J" last="Hazard">Lisa J. Hazard</name><affiliation wicri:level="2"><nlm:affiliation>Department of Radiation Oncology, University of Utah Medical Center, Salt Lake City, UT 84143, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, University of Utah Medical Center, Salt Lake City, UT 84143</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Sause, William T" sort="Sause, William T" uniqKey="Sause W" first="William T" last="Sause">William T. Sause</name></author><author><name sortKey="Noyes, R Dirk" sort="Noyes, R Dirk" uniqKey="Noyes R" first="R Dirk" last="Noyes">R Dirk Noyes</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11849803</idno><idno type="pmid">11849803</idno><idno type="wicri:Area/PubMed/Corpus">004655</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004655</idno><idno type="wicri:Area/PubMed/Curation">004655</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004655</idno><idno type="wicri:Area/PubMed/Checkpoint">004655</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004655</idno><idno type="wicri:Area/Ncbi/Merge">000874</idno><idno type="wicri:Area/Ncbi/Curation">000874</idno><idno type="wicri:Area/Ncbi/Checkpoint">000874</idno><idno type="wicri:doubleKey">0360-3016:2002:Hazard L:combined:adjuvant:radiation</idno><idno type="wicri:Area/Main/Merge">009858</idno><idno type="wicri:Area/Main/Curation">009485</idno><idno type="wicri:Area/Main/Exploration">009485</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.</title><author><name sortKey="Hazard, Lisa J" sort="Hazard, Lisa J" uniqKey="Hazard L" first="Lisa J" last="Hazard">Lisa J. Hazard</name><affiliation wicri:level="2"><nlm:affiliation>Department of Radiation Oncology, University of Utah Medical Center, Salt Lake City, UT 84143, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, University of Utah Medical Center, Salt Lake City, UT 84143</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Sause, William T" sort="Sause, William T" uniqKey="Sause W" first="William T" last="Sause">William T. Sause</name></author><author><name sortKey="Noyes, R Dirk" sort="Noyes, R Dirk" uniqKey="Noyes R" first="R Dirk" last="Noyes">R Dirk Noyes</name></author></analytic><series><title level="j">International journal of radiation oncology, biology, physics</title><idno type="ISSN">0360-3016</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antineoplastic Agents (adverse effects)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Humans</term><term>Interferon-alpha (adverse effects)</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Melanoma (radiotherapy)</term><term>Middle Aged</term><term>Radiation Injuries (etiology)</term><term>Radiotherapy, Adjuvant</term><term>Recombinant Proteins</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (radiotherapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (effets indésirables)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Humains</term><term>Interféron alpha (effets indésirables)</term><term>Interféron alpha (usage thérapeutique)</term><term>Lésions radio-induites (étiologie)</term><term>Mâle</term><term>Mélanome (radiothérapie)</term><term>Mélanome (traitement médicamenteux)</term><term>Protéines recombinantes</term><term>Radiothérapie adjuvante</term><term>Tumeurs cutanées (radiothérapie)</term><term>Tumeurs cutanées (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Radiation Injuries</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lésions radio-induites</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Radiotherapy, Adjuvant</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Humains</term><term>Mâle</term><term>Protéines recombinantes</term><term>Radiothérapie adjuvante</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Surgically resected melanoma patients with high-risk features commonly receive adjuvant therapy with interferon-alpha 2b combined with radiation therapy; the purpose of our study was to evaluate the potential enhancement of radiation toxicity by interferon.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Utah</li></region></list><tree><noCountry><name sortKey="Noyes, R Dirk" sort="Noyes, R Dirk" uniqKey="Noyes R" first="R Dirk" last="Noyes">R Dirk Noyes</name><name sortKey="Sause, William T" sort="Sause, William T" uniqKey="Sause W" first="William T" last="Sause">William T. Sause</name></noCountry><country name="États-Unis"><region name="Utah"><name sortKey="Hazard, Lisa J" sort="Hazard, Lisa J" uniqKey="Hazard L" first="Lisa J" last="Hazard">Lisa J. Hazard</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009485 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009485 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11849803
|texte= Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11849803" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |